Published in Prev Med on July 01, 2002
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The case for early detection. Nat Rev Cancer (2003) 6.96
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res (2003) 4.13
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Nine-year prospective relationship between parental smoking cessation and children's daily smoking. Addiction (2003) 3.14
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med (2010) 2.58
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology (2002) 2.36
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol (2002) 1.84
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev (2002) 1.57
Use of the American College of Radiology BI-RADS to report on the mammographic evaluation of women with signs and symptoms of breast disease. Radiology (2002) 1.53
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res (2006) 1.52
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Complementary and alternative medicine provider use and expenditures by cancer treatment phase. Am J Manag Care (2008) 1.51
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One (2011) 1.50
Prospective prediction of children's smoking transitions: role of parents' and older siblings' smoking. Addiction (2006) 1.49
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol (2007) 1.46
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett (2007) 1.46
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics (2003) 1.44
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Mammography surveillance following breast cancer. Breast Cancer Res Treat (2003) 1.33
Nine-year prediction of adolescent smoking by number of smoking parents. Addict Behav (2005) 1.32
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods (2006) 1.32
Use of the American College of Radiology BI-RADS guidelines by community radiologists: concordance of assessments and recommendations assigned to screening mammograms. AJR Am J Roentgenol (2002) 1.32
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett (2006) 1.25
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res (2009) 1.24
Wnt4/β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res (2010) 1.24
Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin Cancer Res (2008) 1.23
Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer (2003) 1.22
Analysis of the cost-effectiveness of mammography promotion by volunteers in rural communities. Health Educ Behav (2002) 1.19
Childhood friends who smoke: do they influence adolescents to make smoking transitions? Addict Behav (2005) 1.18
Prevalence and characteristics of smokers at 30 Pacific Northwest colleges and universities. Nicotine Tob Res (2007) 1.18
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology (2011) 1.16
The relationship between perceived risk, affect, and health behaviors. Cancer Detect Prev (2004) 1.11
Ovarian cancer early detection claims are biased. Clin Cancer Res (2008) 1.10
CA125 in ovarian cancer. Biomark Med (2007) 1.10
Changes in the influence of parents' and close friends' smoking on adolescent smoking transitions. Addict Behav (2006) 1.10
Parents' and older siblings' smoking during childhood: changing influences on smoking acquisition and escalation over the course of adolescence. Nicotine Tob Res (2007) 1.10
Effectiveness of telephone counseling for mammography: results from five randomized trials. Prev Med (2002) 1.08
Examining the cost-effectiveness of cancer screening promotion. Cancer (2004) 1.07
Heavy smokers: a qualitative analysis of attitudes and beliefs concerning cessation and continued smoking. Nicotine Tob Res (2003) 1.07
Breast cancer risk counseling improves women's functioning. Patient Educ Couns (2004) 1.06
Changes in cancer worry associated with participation in ovarian cancer screening. Psychooncology (2007) 1.04
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol (2011) 1.02
Optimism, perceived risk of breast cancer, and cancer worry among a community-based sample of women. Health Psychol (2004) 1.01
Nine-year prospective association between older siblings' smoking and children's daily smoking. J Adolesc Health (2003) 0.99
Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res (2007) 0.97
Psychological and social risk factors in adolescent smoking transitions: a population-based longitudinal study. Health Psychol (2009) 0.97
The role of schoolmates' smoking and non-smoking in adolescents' smoking transitions: a longitudinal study. Addiction (2007) 0.95
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proc Natl Acad Sci U S A (2013) 0.95
Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol (2011) 0.94
Does parental smoking cessation encourage their young adult children to quit smoking? A prospective study. Addiction (2005) 0.93
DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol (2008) 0.93
Information women receive about heart attacks and how it affects their knowledge, beliefs, and intentions to act in a cardiac emergency. Health Care Women Int (2002) 0.93
Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells (2009) 0.93
A qualitative study of attitudes, beliefs, and practices among 40 undergraduate smokers. J Am Coll Health (2007) 0.92
Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med (2008) 0.91
Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) (2010) 0.91
Clemastine potentiates the human P2X7 receptor by sensitizing it to lower ATP concentrations. J Biol Chem (2011) 0.90
Using a population-based cancer registry for recruitment of newly diagnosed patients with ovarian cancer. Am J Clin Oncol (2005) 0.89
Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. Cancer Biomark (2006) 0.89
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecol Oncol (2011) 0.88
Fear of falling, balance confidence and health-related quality of life in individuals with postpolio syndrome. Physiother Theory Pract (2006) 0.88
Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. PLoS One (2010) 0.87
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) (2012) 0.86
Influence of the pre-operative time in upright sitting position and the needle type on the incidence of post-dural puncture headache (PDPH) in patients receiving a spinal saddle block for anorectal surgery. Int J Colorectal Dis (2010) 0.85
Preferred smoking policies at 30 Pacific Northwest colleges. Public Health Rep (2006) 0.84
Antifouling surface layers for improved signal-to-noise of particle-based immunoassays. Langmuir (2009) 0.84
Worry about ovarian cancer risk and use of screening by high-risk women: how you recruit affects what you find. Am J Med Genet A (2004) 0.84
Activation of the MEK-S6 pathway in high-grade ovarian cancers. Appl Immunohistochem Mol Morphol (2010) 0.82
Recruiting patients with breast cancer and their families to behavioral research in the post-HIPAA period. Oncol Nurs Forum (2007) 0.82
When will I get my breath back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer. Lung Cancer (2012) 0.82
No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev (2009) 0.81
Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev (2004) 0.81
Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. J Am Diet Assoc (2011) 0.79
A case-based clinician training program for treating tobacco use in college students. Public Health Rep (2006) 0.79
Preparedness for cardiac emergencies among Cambodians with limited English proficiency. J Community Health (2012) 0.79
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. Gynecol Oncol (2009) 0.79